368 related articles for article (PubMed ID: 21502559)
21. Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma. A French experience.
Grassin F; Paleiron N; André M; Caliandro R; Bretel JJ; Terrier P; Margery J; Le Chevalier T; Ruffié P
J Thorac Oncol; 2010 Jun; 5(6):893-7. PubMed ID: 20521356
[TBL] [Abstract][Full Text] [Related]
22. A Phase II Study of Pemetrexed in Patients with Recurrent Thymoma and Thymic Carcinoma.
Gbolahan OB; Porter RF; Salter JT; Yiannoutsos C; Burns M; Chiorean EG; Loehrer PJ
J Thorac Oncol; 2018 Dec; 13(12):1940-1948. PubMed ID: 30121390
[TBL] [Abstract][Full Text] [Related]
23. Key components of chemotherapy for thymic malignancies: a systematic review and pooled analysis for anthracycline-, carboplatin- or cisplatin-based chemotherapy.
Okuma Y; Saito M; Hosomi Y; Sakuyama T; Okamura T
J Cancer Res Clin Oncol; 2015 Feb; 141(2):323-31. PubMed ID: 25146529
[TBL] [Abstract][Full Text] [Related]
24. High-dose carboplatin with etoposide in patients with recurrent thymoma: the Indiana University experience.
Hanna N; Gharpure VS; Abonour R; Cornetta K; Loehrer PJ
Bone Marrow Transplant; 2001 Sep; 28(5):435-8. PubMed ID: 11593315
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.
Pujade-Lauraine E; Guastalla JP; Weber B; Curé H; Orfeuvre H; Mousseau M; Vincent P; Diéras V; Tubiana-Mathieu N; Jacquin JP; Mignot L; Leduc B; Paraïso D; Viens P
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-30-S15-35. PubMed ID: 9346219
[TBL] [Abstract][Full Text] [Related]
26. A prospective phase II study of carboplatin and nab-paclitaxel in patients with advanced non-small cell lung cancer and concomitant interstitial lung disease (HOT1302).
Asahina H; Oizumi S; Takamura K; Harada T; Harada M; Yokouchi H; Kanazawa K; Fujita Y; Kojima T; Sugaya F; Tanaka H; Honda R; Kikuchi E; Ikari T; Ogi T; Shimizu K; Suzuki M; Konno S; Dosaka-Akita H; Isobe H; Nishimura M;
Lung Cancer; 2019 Dec; 138():65-71. PubMed ID: 31654836
[TBL] [Abstract][Full Text] [Related]
27. Sequential combination of paclitaxel-carboplatin and paclitaxel-liposomal doxorubicin as a first-line treatment in patients with ovarian cancer. A multicenter phase II trial.
Potamianou A; Androulakis N; Papakotoulas P; Toufexi H; Latoufis C; Kouroussis C; Christofilakis C; Xenidis N; Georgoulias V; Polyzos A
Oncology; 2005; 69(4):348-53. PubMed ID: 16293974
[TBL] [Abstract][Full Text] [Related]
28. Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial.
Thomas A; Rajan A; Berman A; Tomita Y; Brzezniak C; Lee MJ; Lee S; Ling A; Spittler AJ; Carter CA; Guha U; Wang Y; Szabo E; Meltzer P; Steinberg SM; Trepel JB; Loehrer PJ; Giaccone G
Lancet Oncol; 2015 Feb; 16(2):177-86. PubMed ID: 25592632
[TBL] [Abstract][Full Text] [Related]
29. Carboplatin and paclitaxel in advanced or metastatic endometrial cancer.
Pectasides D; Xiros N; Papaxoinis G; Pectasides E; Sykiotis C; Koumarianou A; Psyrri A; Gaglia A; Kassanos D; Gouveris P; Panayiotidis J; Fountzilas G; Economopoulos T
Gynecol Oncol; 2008 May; 109(2):250-4. PubMed ID: 18299146
[TBL] [Abstract][Full Text] [Related]
30. Salvage chemotherapy with carboplatin and paclitaxel for cisplatin-resistant thymic carcinoma--three cases.
Komatsu Y; Koizumi T; Tanabe T; Hatayama O; Yasuo M; Okada M; Yamamoto H; Kubo K; Sasabayashi M; Tsunoda T
Anticancer Res; 2006; 26(6C):4851-5. PubMed ID: 17214351
[TBL] [Abstract][Full Text] [Related]
31. Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas (CAVEATT): a single-arm, multicentre, phase 2 trial.
Conforti F; Zucali PA; Pala L; Catania C; Bagnardi V; Sala I; Della Vigna P; Perrino M; Zagami P; Corti C; Stucchi S; Barberis M; Guerini-Rocco E; Di Venosa B; De Vincenzo F; Cordua N; Santoro A; Giaccone G; De Pas TM
Lancet Oncol; 2022 Oct; 23(10):1287-1296. PubMed ID: 36096156
[TBL] [Abstract][Full Text] [Related]
32. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial.
Socinski MA; Bondarenko I; Karaseva NA; Makhson AM; Vynnychenko I; Okamoto I; Hon JK; Hirsh V; Bhar P; Zhang H; Iglesias JL; Renschler MF
J Clin Oncol; 2012 Jun; 30(17):2055-62. PubMed ID: 22547591
[TBL] [Abstract][Full Text] [Related]
33. Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: an Eastern Cooperative Oncology Group Phase II Trial.
Loehrer PJ; Wang W; Johnson DH; Aisner SC; Ettinger DS;
J Clin Oncol; 2004 Jan; 22(2):293-9. PubMed ID: 14722038
[TBL] [Abstract][Full Text] [Related]
34. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.
Vasey PA; Jayson GC; Gordon A; Gabra H; Coleman R; Atkinson R; Parkin D; Paul J; Hay A; Kaye SB;
J Natl Cancer Inst; 2004 Nov; 96(22):1682-91. PubMed ID: 15547181
[TBL] [Abstract][Full Text] [Related]
35. Cisplatin, doxorubicin, and cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma: an intergroup trial.
Loehrer PJ; Chen M; Kim K; Aisner SC; Einhorn LH; Livingston R; Johnson D
J Clin Oncol; 1997 Sep; 15(9):3093-9. PubMed ID: 9294472
[TBL] [Abstract][Full Text] [Related]
36. Paclitaxel by 24- or 1-hour infusion n combination with carboplatin in advanced non-small cell lung cancer: the Fox Chase Cancer Center experience.
Langer CJ; Leighton JC; Comis RL; O'Dwyer PJ; McAleer CA; Bonjo CA; Engstrom PF; Litwin S; Johnson S; Ozols RF
Semin Oncol; 1995 Aug; 22(4 Suppl 9):18-29. PubMed ID: 7544025
[TBL] [Abstract][Full Text] [Related]
37. Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group.
Loehrer PJ; Kim K; Aisner SC; Livingston R; Einhorn LH; Johnson D; Blum R
J Clin Oncol; 1994 Jun; 12(6):1164-8. PubMed ID: 8201378
[TBL] [Abstract][Full Text] [Related]
38. An Open-Label, Randomized, Controlled Phase II Study of Paclitaxel-Carboplatin Chemotherapy With Necitumumab Versus Paclitaxel-Carboplatin Alone in First-Line Treatment of Patients With Stage IV Squamous Non-Small-Cell Lung Cancer.
Spigel DR; Luft A; Depenbrock H; Ramlau R; Khalil M; Kim JH; Mayo C; Chao GY; Obasaju C; Natale R
Clin Lung Cancer; 2017 Sep; 18(5):480-488. PubMed ID: 28365238
[TBL] [Abstract][Full Text] [Related]
39. A Phase II, randomized, double-blind study of zibotentan (ZD4054) in combination with carboplatin/paclitaxel versus placebo in combination with carboplatin/paclitaxel in patients with advanced ovarian cancer sensitive to platinum-based chemotherapy (AGO-OVAR 2.14).
Cognetti F; Bagnato A; Colombo N; Savarese A; Scambia G; Sehouli J; Wimberger P; Sorio R; Harter P; Mari E; McIntosh S; Nathan F; Pemberton K; Baumann K
Gynecol Oncol; 2013 Jul; 130(1):31-7. PubMed ID: 23234805
[TBL] [Abstract][Full Text] [Related]
40. Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma.
Redman BG; Smith DC; Flaherty L; Du W; Hussain M
J Clin Oncol; 1998 May; 16(5):1844-8. PubMed ID: 9586899
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
